投资者可于 2025 年 9 月 19 日（星期五）至 9 月 25 日（星期四）16:00 前登 录 上 证 路 演 中 心 网 站 首 页 点 击 " 提 问 预 征 集 " 栏 目 或 通 过 公 司 邮 箱 shcred@online.sh.cn 进行提问。公司将在说明会上对投资者普遍关注的问题进 行回答。 证券代码：600833 证券简称：第一医药 公告编号：临 2025-045 上海第一医药股份有限公司 关于召开 2025 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2025 年 9 月 26 日（星期五）下午 15:00-16:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 上海第一医药股份有限公司（以下简称"公司"）已于 2025 年 8 月 20 日发 布公司 2025 年半年度报告，为便于广大投资者 ...

Market Overview - The pharmaceutical commercial sector increased by 0.19% on September 16, with Saily Medical leading the gains [1] - The Shanghai Composite Index closed at 3861.87, up 0.04%, while the Shenzhen Component Index closed at 13063.97, up 0.45% [1] Top Gainers - Saily Medical (603716) closed at 31.80, up 5.75% with a trading volume of 461,500 shares and a transaction value of 1.457 billion [1] - First Pharmaceutical (600833) closed at 14.33, up 3.47% with a trading volume of 159,400 shares and a transaction value of 229 million [1] - Ruikang Pharmaceutical (002589) closed at 3.05, up 2.35% with a trading volume of 564,800 shares and a transaction value of 170 million [1] Other Notable Stocks - Haiwang Biological (000078) closed at 2.72, up 1.87% with a trading volume of 472,600 shares and a transaction value of 128 million [1] - Yiyigou (300937) closed at 28.06, up 1.41% with a trading volume of 13,100 shares and a transaction value of 36.54 million [1] Market Capital Flow - The pharmaceutical commercial sector saw a net inflow of 1.0663 million from institutional investors, while retail investors had a net inflow of 3.2772 million [2] - However, speculative funds experienced a net outflow of 33.8383 million [2] Individual Stock Capital Flow - Saily Medical had a net inflow of 99.8444 million from institutional investors, while it faced a net outflow of 39.1679 million from speculative funds [3] - First Pharmaceutical saw a net inflow of 21.4721 million from institutional investors, but a net outflow of 2.02355 million from retail investors [3] - Ruikang Pharmaceutical had a net inflow of 8.2730 million from institutional investors, with a slight net outflow from speculative funds [3]

Group 1 - The core viewpoint of the news is that Shanghai First Pharmaceutical Co., Ltd. experienced a stock price increase of 5.2%, reaching 14.57 yuan per share, with a total market capitalization of 3.25 billion yuan [1] - The company is primarily engaged in pharmaceutical retail and wholesale, established in 1992 and listed in 1994 [1] - The trading volume for the stock was 130 million yuan, with a turnover rate of 4.07% [1] Group 2 - According to data, GF Fund's Guangfa Innovation Upgrade Mixed Fund (002939) entered the top ten circulating shareholders of First Pharmaceutical, holding 2.7467 million shares, which is 1.23% of the circulating shares [2] - The fund has achieved a year-to-date return of 35.77% and a one-year return of 77.71%, ranking 1923 out of 8174 and 1157 out of 7982 in its category, respectively [2] - Since its inception, the fund has generated a return of 155.89% [2] Group 3 - The fund manager Liu Gesong has a tenure of 12 years and 28 days, with a total fund asset size of 29.462 billion yuan and a best return of 145.13% during his tenure [3] - Co-manager Wu Yuanyi has a tenure of 4 years and 353 days, managing assets of 20.478 billion yuan, with a best return of 107.14% [3]

Market Overview - On September 12, the pharmaceutical commercial sector declined by 0.51%, with Baiyang Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3883.69, up 0.22%, while the Shenzhen Component Index closed at 12996.38, up 0.13% [1] Stock Performance - Key stocks in the pharmaceutical commercial sector showed varied performance, with Seer Medical (603716) leading with a 10.01% increase, closing at 31.31 [1] - Other notable performers included Haiwang Biological (000078) with a 2.69% increase and Runda Medical (603108) with a 1.30% increase [1] Capital Flow - The pharmaceutical commercial sector saw a net inflow of 295 million yuan from institutional investors, while retail investors experienced a net outflow of 113 million yuan [2] - Major stocks like Seer Medical had a significant net inflow of 5.15 billion yuan from institutional investors, while retail investors showed a net outflow of 2.61 billion yuan [2]

Meeting Overview - The shareholders' meeting of Shanghai First Pharmaceutical Co., Ltd. was held on September 4, 2025, at the company's office in Shanghai [1] - The meeting was presided over by the vice chairman, Mr. Yao Jun, due to the absence of the chairman, Mr. Zhang Haibo [1] - The voting method combined on-site and online voting, complying with relevant laws and regulations [1] Voting Results - Two ordinary resolutions were presented and approved by the shareholders present at the meeting [2] - For the first resolution regarding the appointment of the auditing firm, 112,412,276 votes (99.7660%) were in favor, with 244,350 votes (0.2169%) against, and 19,300 votes (0.0171%) abstaining [2] - For the second resolution concerning the reappointment of the internal control auditing firm, 112,411,876 votes (99.7657%) were in favor, with 244,750 votes (0.2172%) against, and 19,300 votes (0.0171%) abstaining [2] Legal Compliance - The meeting's procedures, participant qualifications, proposals, and voting processes were confirmed to comply with the Company Law, Securities Law, and other relevant regulations [4] - The resolutions passed during the meeting were deemed legal and valid [4]

Group 1 - The company announced the convening of its second extraordinary general meeting of shareholders for 2025 on September 4, 2025 [2] - The meeting will review and approve the proposal regarding the reappointment of the internal control auditing accounting firm [2]

证券代码：600833 证券简称：第一医药 公告编号：2025-044 2025年第二次临时股东会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一)股东会召开的时间：2025 年 9 月 4 日 (二)股东会召开的地点：上海市徐汇区小木桥路 681 号 20 楼第三会议室 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 143 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 112,675,926 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | 50.5078 | | 份总数的比例（%） | | 上海第一医药股份有限公司 审议结果：通过 (四) 表决方式是否符合《公司法》及《公司章程》的规定，股东会主持情况 等。 因公司董事长张海波先生另有公务，本次会议由公司副董事长姚军先生主持。 会议采用现场投票及网络投票相结合的方式表决， ...

Core Viewpoint - The legal opinion letter confirms the legality and validity of the procedures, qualifications, proposals, and voting results of the Shanghai First Pharmaceutical Co., Ltd. 2025 Second Extraordinary General Meeting of Shareholders held on September 4, 2025 [1][6]. Group 1: Meeting Summons - The company announced the convening of the 2025 Second Extraordinary General Meeting of Shareholders on August 20, 2025, via the Shanghai Stock Exchange website [3]. - The meeting was scheduled to take place on September 4, 2025, with all necessary details communicated to shareholders 15 days prior [3]. Group 2: Meeting Proceedings - The meeting was held at the designated location, and the voting time was set for the trading hours of September 4, 2025, from 9:15 to 9:25 [3][4]. - Specific voting procedures for margin trading and other related accounts were outlined in accordance with regulatory guidelines [3]. Group 3: Attendance and Voting - A total of 2 shareholders and their representatives attended the meeting, representing 100,854,234 shares with voting rights, which accounted for a significant portion of the total voting shares [4]. - Additionally, 141 shareholders participated in the voting through an online system, with their qualifications verified by the system provider [5]. Group 4: Proposals and Voting Results - The meeting included proposals such as the reappointment of the internal control auditing accounting firm, which were approved by a majority of the voting rights present [5]. - The voting results were announced, confirming that all resolutions passed were in compliance with relevant laws and regulations [5][6]. Group 5: Conclusion - The legal opinion concludes that all aspects of the meeting, including the summons, proceedings, attendance, proposals, and voting, adhered to the applicable laws and the company's articles of association, rendering the resolutions valid [6].

上海市金茂律师事务所 关于上海第一医药股份有限公司 2025 年第二次临时股东会的 法律意见书 致：上海第一医药股份有限公司 （引言） 上海第一医药股份有限公司（以下简称"公司"）2025 年第二次临时股东 会（以下简称"本次股东会"）于 2025 年 9 月 4 日在上海市徐汇区小木桥路 681 号 20 楼第三会议室召开。上海市金茂律师事务所经公司聘请委派韩春燕律 师、路遥律师（以下简称"本所律师"）出席会议，就本次股东会的召集、召开 程序，出席会议人员资格，会议议案，以及会议的表决程序、表决结果等发表法 律意见。 本法律意见书根据《中华人民共和国公司法（2023 修订）》（以下简称"《公 司法》"）、《中华人民共和国证券法（2019 修订）》（以下简称"《证券法》"）、 《上市公司股东会规则》（以下简称"《股东会规则》"）、《上海证券交易所 上市公司自律监管指引第 1 号——规范运作（2025 年 5 月修订）》（以下简称 "《自律监管指引 1 号》"）等有关法律、法规和规范性文件以及《上海第一医 药股份有限公司章程》（以下简称"《公司章程》"）而出具。 二、 本次股东会的召开 为出具本法律意见书，本所 ...

Market Overview - The pharmaceutical commercial sector experienced a slight decline of 0.07% on September 4, with Saily Medical leading the drop [1] - The Shanghai Composite Index closed at 3765.88, down 1.25%, while the Shenzhen Component Index closed at 12118.7, down 2.83% [1] Stock Performance - Notable gainers in the pharmaceutical commercial sector included: - HeFu China (603122) with a closing price of 6.66, up 1.99% [1] - JianZhiJia (605266) at 21.56, up 1.84% [1] - YiXinTang (002727) at 14.98, up 1.70% [1] - Saily Medical (603716) was the biggest loser, closing at 29.00, down 2.26% [2] Trading Volume and Value - The trading volume and value for selected stocks were as follows: - YiXinTang (002727) had a trading volume of 144,800 hands and a transaction value of 216 million [1] - Saily Medical (603716) recorded a trading volume of 256,800 hands with a transaction value of 759 million [2] Capital Flow - The pharmaceutical commercial sector saw a net outflow of 169 million from institutional investors, while retail investors had a net inflow of 210 million [2] - Key stocks with significant capital flow included: - BaiYang Pharmaceutical (301015) with a net inflow of 15.09 million from institutional investors [3] - LaoBaiXing (603883) with a net inflow of 13.41 million from institutional investors [3]